RRML - A new assay to identify recurrent mutations in acute myeloid leukemia using next-generation sequencing

ISSN online: 2284-5623

ISSN-L: 1841-6624

Rejection rate (2020): 75%

Română English

Journal Metrics

Impact Factor 0.493
Five Year Impact Factor 0.531
SNIP 0.373
JCI 0.17

Advanced search

Top 10 downloaded articles
- February 2023 -
On the relationship between CT... 6
The Role of procollagen type 1... 6
Association of HLA class II al... 5
Making the most out of profici... 5
Management of a case of Castle... 5
The Role of Prostate-Specific ... 3
Ischemia modified albumin in e... 3
The potential of programmed de... 3
Atellica CH 930 chemistry anal... 3
Ferritin and procalcitonin in ... 3

Log in

Concept, Design & Programming
Dr. Adrian Man

Nr. 22(1)/2014 DOI:10.2478/rrlm-2014-0003

A new assay to identify recurrent mutations in acute myeloid leukemia using next-generation sequencing

Daniel Coriu, Dumitru Jardan, Cerasela Jardan, Rodica Tălmaci, Mihaela Dragomir, Anca Coliţă


Introduction: Acute myeloid leukemia (AML) is a heterogeneous disease characterized by a late onset (it is rare in children), aggressive phenotype and dismal prognosis especially in patients in the older group (>65 years). For risk stratification of patients standard cytogenetic is used along with molecular techniques for point mutation identification. Here we describe a new method using next generation sequencing for identification of mutation in 5 AML recurrently mutated genes - RUNX1, FLT3, DNMT3A, IDH1 and IDH2. Materials and methods: Samples from 40 patients with normal karyotype AML referred to Fundeni Clinical Institute were sequenced. Primer design was performed using LaserGene Genomics suit. Next generation sequencing was performed on MiSeq (Illumina) and results were analyzed using LaserGene Genomics suit. Results of next generation sequencing were compared to Sanger sequencing. Results: No additional mutations were identified in samples from nine patients presenting FLT3-ITD and/or NPM1 mutations. In 25 out of 31 patients with normal karyotype and no FLT3-ITD and NPM1 mutations, we identified mutations in one of the 5 aforementioned genes. All these mutations identified by next generation sequencing were confirmed using the classical Sanger sequencing. Conclusions: We validated a very useful method for mutation identification in AML patients using next generation sequencing. There are many advantages exhibited by this method: it is more cost efficient and it has a higher sensitivity of mutation detection than Sanger sequencing, it has been described as being quantitative and in our case it allowed risk stratification for most of the normal karyotype AML samples which were FLT3-ITD and NPM1 negative.

Keywords: next generation sequencing,AML,recurrent mutations

  PDF Download full text PDF
(369 KB)
How to cite
Coriu D, Jardan D, Jardan C, Tălmaci R, Dragomir M, Coliţă A. A new assay to identify recurrent mutations in acute myeloid leukemia using next-generation sequencing. Rev Romana Med Lab. 2014;22(1):93-9. DOI:10.2478/rrlm-2014-0003